Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials.

Moeber M Mahzari Muhannad Qirnas Alqirnas Moustafa S AlhamadhFaisal AlrasheedAbdulrahman Yousef AlhabeebWedad Al MadaniHussain Aldera

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2024)

Patients suffering from both T2DM and CKD exhibited a significantly enhanced glycemic control when treated with DPP-4 inhibitors in comparison to the control group. Furthermore, no significant difference in the incidence of adverse events was observed between the DPP-4 inhibitors and the control group.

Keyphrases

glycemic control
type diabetes
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
risk factors
weight loss
insulin resistance
skeletal muscle